These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 7911142)
1. Serotonin in panic disorder and social phobia. Sheehan DV; Raj BA; Trehan RR; Knapp EL Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():63-77. PubMed ID: 7911142 [TBL] [Abstract][Full Text] [Related]
2. Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction. Dubovsky SL; Thomas M J Psychosom Res; 1995 May; 39(4):429-44. PubMed ID: 7562673 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. Pelissolo A Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243 [TBL] [Abstract][Full Text] [Related]
4. Antidepressants in panic disorder: clinical and preclinical mechanisms. Nutt DJ J Clin Psychiatry; 1998; 59 Suppl 8():24-8; discussion 29. PubMed ID: 9707159 [TBL] [Abstract][Full Text] [Related]
5. Panic disorder and social phobia: current treatments and new strategies. Davidson JR; Connor KM; Sutherland SM Cleve Clin J Med; 1998; 65 Suppl 1():SI39-44; discussion SI45-7. PubMed ID: 12033205 [TBL] [Abstract][Full Text] [Related]
6. Panic disorder and social phobia: possible implications of comorbid depression for drug therapy. Lydiard RB Anxiety; 1996; 2(2):61-70. PubMed ID: 9160603 [TBL] [Abstract][Full Text] [Related]
7. [Neurobiology and pharmacotherapy of social phobia]. Aouizerate B; Martin-Guehl C; Tignol J Encephale; 2004; 30(4):301-13. PubMed ID: 15538306 [TBL] [Abstract][Full Text] [Related]
9. New findings in the treatment of panic disorder. Westenberg HG; Den Boer JA Pharmacopsychiatry; 1993 May; 26 Suppl 1():30-3. PubMed ID: 8378420 [TBL] [Abstract][Full Text] [Related]
10. Serotonin and panic. Bell CJ; Nutt DJ Br J Psychiatry; 1998 Jun; 172():465-71. PubMed ID: 9828984 [TBL] [Abstract][Full Text] [Related]
13. Serotonin dysfunction syndromes: a functional common denominator for classification of depression, anxiety, and obsessive-compulsive disorder. Benkert O; Wetzel H; Szegedi A Int Clin Psychopharmacol; 1993 Sep; 8 Suppl 1():3-14. PubMed ID: 8254151 [No Abstract] [Full Text] [Related]
14. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Kent JM; Coplan JD; Gorman JM Biol Psychiatry; 1998 Nov; 44(9):812-24. PubMed ID: 9807637 [TBL] [Abstract][Full Text] [Related]
15. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Klein E; Zohar J; Geraci MF; Murphy DL; Uhde TW Biol Psychiatry; 1991 Nov; 30(10):973-84. PubMed ID: 1756202 [TBL] [Abstract][Full Text] [Related]
16. Recent developments in the psychopharmacology of social phobia. Den Boer JA; van Vliet IM; Westenberg HG Eur Arch Psychiatry Clin Neurosci; 1995; 244(6):309-16. PubMed ID: 7772614 [TBL] [Abstract][Full Text] [Related]
18. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. Hedges DW; Brown BL; Shwalb DA; Godfrey K; Larcher AM J Psychopharmacol; 2007 Jan; 21(1):102-11. PubMed ID: 16714326 [TBL] [Abstract][Full Text] [Related]